Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp. Common Stock (symbol: ATNF) represents a pioneering clinical-stage biotechnology company based in Menlo Park, California. The company focuses on developing innovative therapeutics to address unmet medical needs in chronic pain, inflammation, and fibrosis.
The company has several key product development platforms currently in Phase IIb/III clinical trials:
- Fibrosis and Anti-TNF Platform: This platform targets the treatment of fibrosis and anti-tumor necrosis factors, a major cause of inflammation.
- Synthetic Cannabidiol (CBD) Analogs Platform: This platform includes man-made derivatives of CBD designed to offer therapeutic benefits.
- α7nAChR Platform: Focused on the alpha 7 nicotinic acetylcholine receptor, which plays a role in modulating inflammation and pain.
180 Life Sciences Corp. is committed to advancing its drug candidates through robust clinical trials and cutting-edge research. From addressing postoperative pain relief with orally absorbed CBD tablets to combating chronic inflammation and fibrosis, the company's innovative approach highlights its significance in the biotechnology landscape.
The company’s recent achievements include a notable presentation by Dr. Michael J. Alaia at the 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The talk focused on the efficacy of CBD tablets for postoperative pain relief, showcasing the potential impact of 180 Life Sciences Corp.'s therapies.
For more information, investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.
180 Life Sciences Corp. (NASDAQ: ATNF) has received an extension from the Nasdaq Listing Qualifications Panel to regain compliance with continued listing requirements. The company now has until September 20, 2024 to meet the minimum stockholders' equity requirement of $2.5 million. This extension allows 180 Life Sciences to continue trading on Nasdaq while working to meet the Equity Rule.
The company had previously received a delist determination letter on May 14, 2024, but appealed the decision. While the Hearings Panel has granted this extension, there is no guarantee that 180 Life Sciences will meet the deadlines or conditions imposed. The Nasdaq Listing and Hearing Review Council may also review the decision within 45 calendar days.
180 Life Sciences announced that Nasdaq's Hearings Panel has granted the company an extension to regain compliance with Nasdaq's continued listing requirements, particularly the minimum stockholders’ equity rule of $2.5 million, by July 31, 2024. The company was initially notified of non-compliance on November 15, 2023, and was unable to meet the equity requirement by the extended deadline of May 13, 2024. Consequently, a delist determination was issued on May 14, 2024. Following an appeal, the delisting action was stayed pending the Hearings Panel's decision, which has now granted the company additional time to comply. However, there is no guarantee that the company will meet these requirements.
FAQ
What is the current stock price of 180 Life Sciences (ATNF)?
What is the market cap of 180 Life Sciences (ATNF)?
What does 180 Life Sciences Corp. specialize in?
Where is 180 Life Sciences Corp. headquartered?
What are the key platforms of 180 Life Sciences Corp.?
What stage are the company's product development platforms in?
Who can be contacted for investor relations?
What is the focus of the recent talk presented by Dr. Michael J. Alaia?
What is the company's ticker symbol?
What unmet medical needs does 180 Life Sciences Corp. aim to address?
What is the significance of the α7nAChR platform?
How can I stay updated with the latest news about 180 Life Sciences Corp.?
